Related Experiment Video
Updated: Jun 4, 2025

A Porcine Model of Acute Autologous Pulmonary Embolism
Published on: September 6, 2024
A Rational Approach to the Treatment of Acute Pulmonary Embolism
Michela Faggioni1, Jay Giri2,3, Lauren Glassmoyer3
1Division of Cardiovascular Medicine, Department of Medicine, University of California, San Francisco, California, USA.
Acute pulmonary embolism (PE) treatment is complex due to new options but limited guidelines. This review offers a practical approach to PE risk stratification and treatment selection for better patient care.
Area of Science:
- Cardiology
- Pulmonology
- Emergency Medicine
Background:
- Acute pulmonary embolism (PE) is a significant global cause of illness and death.
- Despite advancements in treatment modalities, clinical decision-making for PE remains challenging.
- Lack of robust clinical trial data and definitive guidelines complicates patient management.
Purpose of the Study:
- To present a practical and current approach to managing patients with acute pulmonary embolism.
- To focus on risk stratification strategies for PE patients.
- To guide treatment selection in the context of evolving PE therapies.
Main Methods:
- Review of current literature and clinical guidelines on pulmonary embolism.
- Discussion of risk stratification tools and scores for PE.
- Analysis of emerging and established treatment options for PE.
Main Results:
- New treatment modalities for PE have emerged over the last decade.
- Risk stratification is crucial for tailoring PE treatment.
- Treatment selection requires careful consideration of individual patient factors and available evidence.
Conclusions:
- A structured approach to PE management, emphasizing risk stratification, is essential.
- Clinicians need practical guidance to navigate complex treatment decisions in PE.
- Further research and guideline development are needed to optimize acute pulmonary embolism care.
Related Concept Videos
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Flail Chest-II
Assessment:
1. Clinical Evaluation:
History:
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

